A quantitative assay for the in vitro determination of rat NGAL in urine, plasma, serum, tissue extracts or culture media.

Rat NGAL ELISA Kit

CAT NO: KIT 046

Request Price
×

Request Price

"*" indicates required fields

Name*
Consent*
This field is for validation purposes and should be left unchanged.

Product Summary

Cat. No.
KIT 046
Assay range
4-400 pg/mL
Assay time
<4 hours
Limit of detection
0.5 pg/mL
Sample dilution
1/20,000 (Urine or EDTA plasma, healthy rats)
Species reactivity (positive)
None
Storage
4°C
Target
Rat NGAL (Neutrophil Gelatinase-Associated Lipocalin)
Background
NGAL determination allows kidney injury to be detected almost as soon as it occurs, and not at the later stage when the consequences of impaired kidney function can be detected by existing routine tests and the damage has been consolidated.
Regulatory status
RUO - Research Use Only.
Other information
Kit features highly reproducible and easy-to-use working solutions, ready-to-use calibrators and pre-coated 96-well ELISA plate. All incubations performed at room temperature. Requires only standard ELISA equipment.

Scientific References

23147732 – Pai MP, Chen WZ, Garba A, Cui H, Zaffo B, El-Fawal HA, Mousa SA (2013) Effects of obesity and sex on antimicrobial pharmacokinetics and acute kidney injury: validation of a preclinical model. Antimicrob Agents Chemother. 57:716-722

23364806 – Sohotnik R, Nativ O, Abbasi A, Awad H, Frajewicki V, Bishara B, Sukhotnik I, Armaly Z, Aronson D, Heyman SN, Nativ O, Abassi Z (2013) Phosphodiesterase-5 inhibition attenuates early renal ischemia-reperfusion-induced acute kidney injury: assessment by quantitative measurement of urinary NGAL and KIM-1. Am J Physiol Renal Physiol. 304:1099-1104

23331620 – Sultan S, Cameron S, Ahmad S, Malik IA, Schultze FC, Hielscher R, Rave-Frank M, Hess CF, Ramadori G, Christiansen H (2013) Serum Lipocalin2 is a potential biomarker of liver irradiation damage. Liver Int. 33:459-468

22621967 – Bohn AB, Norregaard R, Stodkilde L, Wang Y, Bertelsen LB, Fenton RA, Matchkov VV, Bouzinova EV, Horsman MR, Frokiaer J, Stodkilde-Jorgensen H (2012) Treatment with the vascular disrupting agent combretastatin is associated with impaired AQP2 trafficking and increased urine output. Am J Physiol Regul Integr Comp Physiol. 303:186-198

22492942 – Giani JF, Burghi V, Veiras LC, Tomat A, Munoz MC, Cao G, Turyn D, Toblli JE, Dominici FP (2012) Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats. Am J Physiol Renal Physiol. 302:1606-1615

Cat. No.
KIT 046
Assay range
4-400 pg/mL
Assay time
<4 hours
Limit of detection
0.5 pg/mL
Sample dilution
1/20,000 (Urine or EDTA plasma, healthy rats)
Species reactivity (positive)
None
Storage
4°C
Target
Rat NGAL (Neutrophil Gelatinase-Associated Lipocalin)
Background
NGAL determination allows kidney injury to be detected almost as soon as it occurs, and not at the later stage when the consequences of impaired kidney function can be detected by existing routine tests and the damage has been consolidated.
Regulatory status
RUO - Research Use Only.
Other information
Kit features highly reproducible and easy-to-use working solutions, ready-to-use calibrators and pre-coated 96-well ELISA plate. All incubations performed at room temperature. Requires only standard ELISA equipment.

23147732 – Pai MP, Chen WZ, Garba A, Cui H, Zaffo B, El-Fawal HA, Mousa SA (2013) Effects of obesity and sex on antimicrobial pharmacokinetics and acute kidney injury: validation of a preclinical model. Antimicrob Agents Chemother. 57:716-722

23364806 – Sohotnik R, Nativ O, Abbasi A, Awad H, Frajewicki V, Bishara B, Sukhotnik I, Armaly Z, Aronson D, Heyman SN, Nativ O, Abassi Z (2013) Phosphodiesterase-5 inhibition attenuates early renal ischemia-reperfusion-induced acute kidney injury: assessment by quantitative measurement of urinary NGAL and KIM-1. Am J Physiol Renal Physiol. 304:1099-1104

23331620 – Sultan S, Cameron S, Ahmad S, Malik IA, Schultze FC, Hielscher R, Rave-Frank M, Hess CF, Ramadori G, Christiansen H (2013) Serum Lipocalin2 is a potential biomarker of liver irradiation damage. Liver Int. 33:459-468

22621967 – Bohn AB, Norregaard R, Stodkilde L, Wang Y, Bertelsen LB, Fenton RA, Matchkov VV, Bouzinova EV, Horsman MR, Frokiaer J, Stodkilde-Jorgensen H (2012) Treatment with the vascular disrupting agent combretastatin is associated with impaired AQP2 trafficking and increased urine output. Am J Physiol Regul Integr Comp Physiol. 303:186-198

22492942 – Giani JF, Burghi V, Veiras LC, Tomat A, Munoz MC, Cao G, Turyn D, Toblli JE, Dominici FP (2012) Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats. Am J Physiol Renal Physiol. 302:1606-1615

Downloads

+

Quick Guide Kit 046

IFU Kit 046

NGAL Product Overview

Non-hazardous statement (SDS)

×